Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- RAVN +6.9%, MOMO +6.4%, CDNA +5.5%, CRMT +5.1%, A +2.8%, TOL +2.6%, TTM +2.4%, DSW +2%, TTWO +1.4%, EVLV +0.9%
Other news:
- TGTX +10% (announces that the DSMB of the UNITY-CLL Phase 3 trial has successfully completed a pre-specified interim analysis)
- NOK +6.3% (Nokia and Apple (AAPL) settle all litigation related to their intellectual property dispute and agreed a multi-year patent license)
- ERIC +4% (in sympathy with NOK)
- OPHT +3.6% (D. E. SHAW increases passive stake to 5.0%)
- SBPH +2.9% (very thinly traded; to host a conference call on Wednesday, May 24, 2017, at 8:00 a.m. ET, to discuss top-line results from the initial 25mg monotherapy dosing cohort of the Phase 2a segment of its ACHIEVE trial)
- GKOS +2.6% (Glaukos reported that study revealed potential cost efficiency of using two Glaukos iStent trabecular micro-bypass stents to treat elevated IOP in glaucoma patients)
- AT +2.1% (light volume; CEO disclosed purchase of 15,489 shares)
- AAOI +0.9% (continued strength)
- TPX +0.9% (Director disclosed purchase of 150K shares worth about $6.90 mln)
Analyst comments:
- WING +3.9% (added to Conviction Buy List at Goldman)
- ATW +3% (upgraded to Neutral from Sell at Goldman)
- CVNA +2.6% (initiated with a Outperform at Wells Fargo, initiated with a Buy at BofA/Merrill, among others)
- CLDR +2.4% (initiated with a Buy at Deutsche Bank)
- RS +1.7% (upgraded to Buy from Neutral at BofA/Merrill)
- MCK +1.1% (upgraded to Overweight from Neutral at JP Morgan)